poisar

Stocks · News reference

Inventiva Completes Final 72-Week NATiV3 Patient Visit With 1,419 Patients Enrolled, Topline Results Expected Q4 2026

BenzingaBenzinga Newsdesk

Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading